Artículos por temáticas

Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease

Uddin MS, Kabir MT, Niaz K, Jeandet P, Clément C, Mathew B, Rauf A, Rengasamy KRR, Sobarzo-Sánchez E, Ashraf GM, Aleya L.

Molecules. 2020 Mar 11;25(6):1267. doi: 10.3390/molecules25061267.

Popular three-dimensional models: Advantages for cancer, Alzheimer's and cardiovascular diseases

Ntamo Y, Samodien E, Muller CJF, Louw J, Chellan N.

Tissue Cell. 2020 Aug;65:101367. doi: 10.1016/j.tice.2020.101367. Epub 2020 Apr 17.

Mitochondrial calcium uniporter as a potential therapeutic strategy for Alzheimer's disease

Venugopal A, Iyer M, Balasubramanian V, Vellingiri B.

Acta Neuropsychiatr. 2020 Apr;32(2):65-71. doi: 10.1017/neu.2019.39. Epub 2019 Dec 26.

Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease

Dogra A, Narang RS, Narang JK.

Curr Pharm Des. 2020;26(19):2257-2279. doi: 10.2174/1381612826666200422092620.

CAR (Current Alzheimer Research) has a ROAD (Research on AD) Even in the Lockdown

Lahiri DK, Farlow MR.

Curr Alzheimer Res. 2020;17(12):1053-1054. doi: 10.2174/156720501712210222105659.

APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer's disease

Lin AL, Parikh I, Yanckello LM, White RS, Hartz AMS, Taylor CE, McCulloch SD, Thalman SW, Xia M, McCarty K, Ubele M, Head E, Hyder F, Sanganahalli BG.

Neurobiol Dis. 2020 Jun;139:104834. doi: 10.1016/j.nbd.2020.104834. Epub 2020 Mar 12.

Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease

Lee H, Kim E.

Arch Pharm Res. 2020 Sep;43(9):932-960. doi: 10.1007/s12272-020-01268-5. Epub 2020 Sep 9.

Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology

Esteras N, Abramov AY.

Cells. 2020 Sep 21;9(9):2135. doi: 10.3390/cells9092135.

Recent Updates in the Alzheimer's Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials

Zarini-Gakiye E, Amini J, Sanadgol N, Vaezi G, Parivar K.

Curr Mol Pharmacol. 2020;13(4):273-294. doi: 10.2174/1874467213666200422090135.

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome

Rueda N, Flórez J, Dierssen M, Martínez-Cué C.

Prog Brain Res. 2020;251:245-268. doi: 10.1016/bs.pbr.2019.10.001. Epub 2019 Nov 1.

Road From Nose to Brain for Treatment of Alzheimer: The Bumps and Humps

Kumar R, Gulati M, Singh SK, Sharma D, Porwal O.

CNS Neurol Disord Drug Targets. 2020;19(9):663-675. doi: 10.2174/1871527319666200708124726.

Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs

Millan MJ, Dekeyne A, Gobert A, Brocco M, Mannoury la Cour C, Ortuno JC, Watson D, Fone KCF.

Neuropharmacology. 2020 Oct 15;177:108099. doi: 10.1016/j.neuropharm.2020.108099. Epub 2020 Jun 7.

The Brain AT2R-a Potential Target for Therapy in Alzheimer's Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics

Ahmed HA, Ishrat T.

Mol Neurobiol. 2020 Aug;57(8):3458-3484. doi: 10.1007/s12035-020-01964-9. Epub 2020 Jun 12.

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer's disease

Angrist M, Yang A, Kantor B, Chiba-Falek O.

Life Sci Soc Policy. 2020 Oct 12;16(1):11. doi: 10.1186/s40504-020-00106-2.

Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's

Nirale P, Paul A, Yadav KS.

Life Sci. 2020 Mar 15;245:117394. doi: 10.1016/j.lfs.2020.117394. Epub 2020 Feb 1.